Current status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCV.
We herein report on the current status of Japanese HIV-positive patients with coagulation disorders, primarily hemophilia, based on the national survey of 31 May 2006. The total number of registered patients was 1,431 (Hemophilia A 1,086; Hemophilia B 325; von Willebrand disease 8; others 12), and 604 of these patients were deceased by 31 May 2006. The survival rate after the beginning of 1983 was evaluated by the Kaplan-Meier method. The total number of surviving patients was 827, and the survival rate on 31 May 2006 was 55.7 +/- 1.4%. Among the 827 surviving patients, HCV antibody was observed in 740, was negative in 16, and was not reported in 71 patients. Thus, the prevalence of HCV infection was 98% in the surviving patients based on the presence of HCV antibody. Among the 604 deceased patients, liver disease was reported as a cause of death in 149 cases (25%), and infection with HCV was reported as the possible cause of liver disease in 120 cases (20%). After 1997, 63 cases among the subtotal of 148 deaths had critical hepatic disease that originated from HCV infection, which accounted for 43% of the subtotal. The cumulative rate of patients who received interferon therapy was 32%. Interferon therapy should be prescribed more frequently to HIV-positive patients with coagulation disorders in order to realize the survival benefits, although clinicians should be aware of side effects and toxicities.
Tatsunami
Shinobu
S
Unit of Medical Statistics, Faculty of Medical Education and Culture, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, 216-8511, Japan. s2tatsu@marianna-u.ac.jp.
Mimaya
Junichi
J
Division of Hematology and Oncology, Children's Hospital of Shizuoka, Shizuoka, 420-8660, Japan.
Shirahata
Akira
A
Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, 807-8555, Japan.
Zelinka
Jiří
J
Department of Mathematics and Statistics, Masaryk University, Kotlarska 2, 61137, Brno, Czech Republic.
Horová
Ivana
I
Department of Mathematics and Statistics, Masaryk University, Kotlarska 2, 61137, Brno, Czech Republic.
Hanai
Jugo
J
Medical Care and Human Rights Network, Osaka, 530-0047, Japan.
Nishina
Yutaka
Y
Nishina and Fukado Law Office, Tokyo, 102-0094, Japan.
Ohira
Katsumi
K
Social Welfare Corporation HABATAKI Welfare Project, Tokyo, 162-0814, Japan.
Taki
Masashi
M
Department of Pediatrics, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, 241-0811, Japan.
D044466:Asian People; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D003625:Data Collection; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D016174:Hepacivirus; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D012042:Registries; D012189:Retrospective Studies; D015996:Survival Rate
D018937:Hepatitis C Antibodies